Related Experiment Video
Updated: Jun 21, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic
William Cruz-Munoz1, Shan Man, Robert S Kerbel
1Sunnybrook Health Sciences Centre, Molecular and Cellular Biology Research, Toronto, Ontario, Canada.
Purpose:
The development of effective therapeutic approaches for treatment of metastatic melanoma remains an immense challenge. Present therapies offer minimal benefit. Although dacarbazine chemotherapy remains the standard therapy, it mediates only low response rates, usually of short duration, even when combined with other chemotherapeutic agents. Thus, new therapeutic strategies are urgently needed.
Experimental Design:
Using a newly developed preclinical model, we evaluated the efficacy of various doublet metronomic combination chemotherapy against established advanced melanoma metastasis and compared these with the standard maximum tolerated dose dacarbazine (alone or in combination with chemotherapeutic agents or vascular endothelial growth factor receptor-blocking antibody).
Results:
Whereas maximum tolerated dose dacarbazine therapy did not cause significant improvement in median survival, a doublet combination of low-dose metronomic vinblastine and low-dose metronomic cyclophosphamide induced a significant increase in survival with only minimal toxicity. Furthermore, we show that the incorporation of the low-dose metronomic vinblastine/low-dose metronomic cyclophosphamide combination with a low-dose metronomic dacarbazine regimen also results in a significant increase in survival, but not when combined with maximum tolerated dose dacarbazine therapy. We also show that a combination of metronomic vinblastine therapy and a vascular endothelial growth factor receptor 2-blocking antibody (DC101) results in significant control of metastatic disease and that the combination of low-dose metronomic vinblastine/DC101 and low-dose metronomic dacarbazine induced a significant improvement in median survival.
Conclusions:
The effective control of advanced metastatic melanoma achieved by these metronomic-based chemotherapeutic approaches warrants clinical consideration of this treatment concept, given the recent results of a number of metronomic-based chemotherapy clinical trials.
Insights
Metronomic chemotherapy with vinblastine and cyclophosphamide significantly improves survival in metastatic melanoma. This approach offers a promising, low-toxicity alternative to standard dacarbazine therapy.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Metastatic melanoma treatment remains challenging, with current therapies offering limited efficacy.
- Dacarbazine chemotherapy, the standard treatment, shows low response rates and short durations, even in combination.
- Novel therapeutic strategies are crucial for improving outcomes in advanced melanoma.
Purpose of the Study:
- To evaluate the efficacy of various doublet metronomic combination chemotherapy regimens.
- To compare metronomic chemotherapy against standard maximum tolerated dose dacarbazine therapy.
- To identify effective therapeutic strategies for advanced melanoma metastasis.
Main Methods:
- A preclinical model of advanced melanoma metastasis was utilized.
- Efficacy of doublet metronomic combination chemotherapy was assessed.
- Comparisons were made with maximum tolerated dose dacarbazine, alone and in combination.
Main Results:
- A doublet combination of low-dose metronomic vinblastine and cyclophosphamide significantly increased survival with minimal toxicity.
- Combining metronomic vinblastine, cyclophosphamide, and dacarbazine also improved survival.
- Metronomic vinblastine combined with a VEGF receptor 2-blocking antibody (DC101) controlled metastatic disease.
Conclusions:
- Metronomic-based chemotherapy demonstrates effective control of advanced metastatic melanoma.
- These findings support clinical consideration of metronomic chemotherapy for melanoma treatment.
- Metronomic approaches represent a promising therapeutic concept for advanced melanoma.
